Royalty Report: Drugs, Cancer, cell therapy – Collection: 298723


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 5


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 5

Primary Industries

  • Drugs
  • Cancer
  • cell therapy
  • Therapeutic
  • Pharmaceuticals

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 298723

License Grant
Licensor of United Kingdom grants to the Licensee of Belgium an exclusive, sublicensable license to Licensor Intellectual Property Rights to research, to have researched, to develop, to have developed, to manufacture, to have manufactured, to sell and to have sold, and generally to use and to have used, Products within the Field in the Territory during the Term.
License Property
Licensor has certain intellectual property and know-how regarding the engineering of primary cells for therapeutic applications.

Products means any allogeneic Chimeric Antigen Receptor T-cell therapy in which cells are modified to knockdown one or more Targets by using shRNA, using Licensor Intellectual Property Rights pursuant to this Agreement, or any other product whose manufacture, use or sale would, in the absence of a license from Licensor, constitute direct, indirect, contributory or any other type of infringement of one or more claims of Licensor Intellectual Property Rights.

The patents include Micro-RNA scaffolds and non-naturally occuring micro-RNAs, and, Micro-RNA scaffolds, non-naturally occurring micro-RNAs, and methods for optimizing non-naturally occurring micro-RNAs.

Field of Use
Field means the treatment of human diseases through allogeneic Chimeric Antigen Receptor CAR-T-cell therapy in which cells are modified to knockdown one or more Targets by using shRNA.

A Phase 1 dose-escalation trial evaluating the safety and clinical activity of CYAD-02 is planned for early 2020 and will involve a preconditioning chemotherapy (CyFlu) in patients with relapse/refractory (r/r) acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS).

IPSCIO Record ID: 362483

License Grant
Licensors, as applicable, grant to Licensee of Switzerland an exclusive, sub-licensable license, under the Licensor IP in the Territory in the Field,
–  to generate and test Chimeric Antigen Receptor T-Cell Products solely for the Development, Regulatory Approval and Commercialization of Products containing such Chimeric Antigen Receptor I-Cell Products;
–  to Develop and Commercialize Products in the Field in the Territory, provided that such Products are not Out-of-Scope Products; and
–  to Commercialize the Chimeric Antigen Receptor for Products.
License Property
Licensor has expertise in and owns or controls proprietary technology relating to genetically engineering cells to target and destroy cancer cells.

Product means any pharmaceutical product containing a Chimeric Antigen Receptor I-Cell Product developed by Licensor under a Research Program for which the JSC determines to file an IND or under a research program for which Licensee has exercised the Licensor Program Option, or, any pharmaceutical product containing a Chimeric Antigen Receptor T-Cell Product developed by or on behalf of Licensee that is a derivative of or is otherwise developed from or based upon a Chimeric Antigen Receptor T-Cell Product described above.

Allogcneic Cell Therapy means a genomically engineered patient-nonspecific T-cell expressing a Chimeric Antigen Receptor for delivery to a patient developed under the Allogeneic Cell Therapy Research Program satisfying the Allogeneic Cell Therapy Criteria.

Chimeric Antigen Receptor T-Cell Product means a T-Cell having a Chimeric Antigen Receptor, or, a T-cell under switch control having a Chimeric Antigen Receptor and any Activator Ligands or Exclusive Activator Ligands that are administered to control such T-cells irrespective of whether such Activator Ligands or Exclusive Activator Ligands are packaged with and/or delivered with such T-cell directed to a Target, or, an Allogeneic Cell Therapy, or, the Allogeneic Cell Therapy under switch control having a Chimeric Antigen Receptor directed to a Target and any Activator Ligands or Exclusive Activator Ligands that are administered to control such Allogeneic Cell Therapy irrespective of whether such Activator Ligands or Exclusive Activator Ligands are packaged with and/or delivered with such Allogeneic Cell Therapy, or, any component sold as a kit, such as a device, delivery system or therapy scheme for the above to modify such T-cell including one or more polypeptides or nucleic acids encoding a CAR.

Licensor Platform Technology means Licensors platform of research tools and technology necessary for Licensor to perform its tasks directed towards the design, identification, culturing, and/or production of genetically modified cells consistent with this Agreement, including without limitation the technology embodied in the Licensor Materials and the Licensor Patents, and specifically including without limitation the following of Licensors platform areas and capabilities
(I) UltraVcctor,
(2) LEAP,
(3) DNA and RNA MOD engineering,
(4) protein engineering,
(5) transcription control chemistry,
(6) genome engineering,
(7) cell system engineering,
(8) Endometrial Regenerative Cells,
(9) the RheoSwitchE technology and RheoSwitch Therapeutic Systems, and
(10) MD Anderson CC Technologies.

Field of Use
The Field means the prophylactic, therapeutic, palliative or diagnostic use for cancer in humans.

IPSCIO Record ID: 26488

License Grant
The Licensor grants to the Licensee worldwide rights to Azacitidine, Vidaza.
License Property
Vidaza is the subject of a completed and published Phase III study indicating its safety and efficacy in the treatment of myelodysplastic syndromes, or MDS, a bone marrow disorder characterized by the production of abnormally functioning, immature blood cells.  The myelodysplastic syndromes are a diverse collection of hematological conditions united by ineffective production (or dysplasia) of myeloid blood cells and risk of transformation to acute myelogenous leukemia or AML.
Field of Use
The field of use relates to the medical industry.

IPSCIO Record ID: 336301

License Grant
Licensor hereby grants to Licensee an exclusive (even as to Licensor and its Affiliates), worldwide, sublicenseable (through multiple tiers), transferable, perpetual and irrevocable license under the Licensor Patents and the Licensor Know-How to Exploit Licensed Products for use in the Field.

This license shall continue in full force and effect, on a country-by-country and Licensed Product-by- Licensed Product basis, until the expiration of all of Licensee’s payment obligations hereunder, after which time Licensee shall retain a perpetual, irrevocable, sublicenseable,  nonexclusive license to any Intellectual Property Rights licensed to Licensee pursuant to the terms of this Agreement during the Term, solely within the scope of the licenses granted to Licensee herein during the Term.

License Property
Licensed Product shall mean any CAR Product utilizing SWITCH Technology that (a) is solely directed against one or more Program Target(s), and (b) (i) is Covered by a Valid Claim within the Licensor Patents, or (ii) the Exploitation of which utilizes the Licensor Know-How. Without limiting the foregoing, Licensed Products (A) shall include all products that fall within the definition of Licensed Products as such term is defined in the UC Licenses, and (B) shall exclude any Bi-Specific Product directed against at least one (1) Target that is not a Program Target.

CAR means a chimeric antigen receptor.

CAR Product means a pharmaceutical or biologic product in any form or composition containing a CAR T-Cell.

CAR T-Cell means an engineered T-Cell that expresses one or more CARs that are directed against a particular Target.

US application #61 /765,585 – Chimeric Antigen Receptor and Methods of use thereof.
US application #62/276,725 – Conditionally Active Heterodimeric Polypeptides and methods of use thereof.
US application #62/212,999 – Modular Polypeptide Libraries and Methods of Making and Using Same.

Field of Use
Field shall mean the treatment, prevention and palliation of all human and animal diseases and disorders, including, without limitation, AML and B-Cell Malignancies.

“AML” means acute myeloid leukemia or acute myelogenous leukemia.

The Licensee will receive rights to develop and commercialize CAR-based product candidates containing Licensor's on/off switches” directed to certain targets that are associated with acute myeloid leukemia.

IPSCIO Record ID: 312594

License Grant
Licensors filed a complaint against Licensee in the U.S. District Court for the Central District of California. The complaint alleged that Yescarta* infringes certain claims of U.S. Patent No. 7,446,190 concerning CAR T cell technologies.

In April 2020, the Court granted in part Licensor’s motion and entered a final judgment awarding royalties on Licensee’s sales of Yescarta* from December 13, 2019 through the expiration of the Patent in August 2024.

License Property
CAR T refers to cell therapy.

Yescarta is a trademark of Licensee.   Yescarta, a CAR T cell therapy, involves (i) harvesting T cells from the patient’s blood, (ii) engineering T cells to express cancer-specific receptors, (iii) increasing the number of engineered T cells and (iv) infusing the functional cancer-specific T cells back into the patient.

Field of Use
Yescarta is cell therapy used in the treatment of cancer.  Licensee is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.